Citations

Clear

6 citation(s) found for "Sinai, Erin".

Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities
Laule, Cornelia , Cohen-Adad, Julien, Witt, Atlee , Luca, Gabriele C. De, Granziera, Cristina , Keegan, B. Mark , Kerbrat, Anne , Klawiter, Eric C, Kolind, Shannon , O’Grady, Kristin P. , Oh, Jiwon, Sivakolundu, Dinesh K. , Smith, Seth A, Vavasour, Irene M, Mainero, Caterina , Alonso-Ortiz, Eva, Krieger, Stephen , Li, David , Shinohara, Russell T, Henry, Roland G, Cooperative, North American Imaging in Multiple Sclerosis (NAIMS), Witt, Atlee A , De Luca, Gabriele C , Bagnato, Francesca R. , Gauthier, Susan A , Bakshi, Rohit , Beck, Erin S , Krieger, Stephen , Keegan, B Mark , Kollind, Shannon H , Granziera, Cristina , O'Grady, Kristin P , Cohen-Adad, Julien , DeLuca, Gabriele C. , Kerbrat, Anne , Klawiter, Eric C. , Oh, Jiwon , Schilling, Kurt G. , Smith, Seth A. , Tozlu, Ceren , Vavasour, Irene M. , Alonso‐Ortiz, Eva , Brier, Matthew R. , Hemond, Christopher C , Li, David K.B. , Shinohara, Russell Taki , Henry, Roland G.

Mayo Clinic

Multiple Sclerosis Journal | June 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/13524585261444600 | PMID 42224274 Get It

The spinal cord plays a central role in the pathophysiology and clinical manifestations of multiple sclerosis (MS), yet remains under-studied compared with the brain. This review summarizes key insights from the 2025 North American Imaging in MS Spinal Cord Imaging Workshop, highlighting recent advances, ongoing challenges, and future opportunities in MS spinal cord imaging. We review pathological studies and outline the clinical relevance of spinal cord lesions and atrophy for diagnosis, prognosis, and disease monitoring, highlighting emerging biomarkers of progression independent of relapse activity. Correlations between magnetic resonance imaging, histopathology, and clinical outcomes support the validation and translational potential of advanced spinal cord imaging techniques. Finally, we discuss spinal cord–specific processing pipelines and reproducibility challenges. Collectively, these insights underscore the need to integrate advanced and quantitative spinal cord imaging into clinical trials, research studies, and—when feasible—clinical care, to fully capture the extent of MS pathology, and ultimately improve patient outcomes.
Eosinophilic Gastrointestinal Disease After Pediatric Organ and Bone Marrow Transplantation
Sinai, Erin , Wilson, Bridget E. , Pecak, Melissa, Schroeder, Shauna , Bauer, Cindy S., Swing, Edward Lee

Mayo Clinic

JGH Open | January 26, 2026 | Volume: 10 | Issue: 1 | Pages: No page available

10.1002/jgh3.70344 | PMID 41602586 Get It

ABSTRACT Background Previous studies have shown an increased prevalence of eosinophilic gastrointestinal disease (EGID) in pediatric liver and heart transplant recipients. However, EGID after other solid organ and bone marrow transplantations has not been extensively evaluated. Aims The purpose of this study is to determine relationships between subsets of EGID with different solid organ and bone marrow transplants in pediatric patients. Methods We performed a single‐center retrospective chart review of pediatric patients with transplant and EGID between 2007 and 2023. For comparison between transplant groups, ANOVA was used for statistical analysis of continuous variables, and Fisher's exact test was used for categorical variables. Results There were 30 patients with EGID (eosinophilic esophagitis [EoE] = 21; eosinophilic gastritis [EoG] = 4; EoE + EoG = 3; EoE + eosinophilic colitis [EoC] = 1; eosinophilic duodenitis [EoD] = 1) and history of transplant (liver = 15; heart = 9; bone marrow = 3; multivisceral liver + small bowel + pancreas = 2; kidney = 1). When comparing the transplant groups, there was a significant difference in EoE + EoG incidence ( p = 0.011), specifically, EoE + EoG was present in 2 (100%) multivisceral and in 1/15 (7%) liver transplant patients. A statistically significant difference in the presence of gastroesophageal reflux (GER) and oral allergy syndrome between groups was noted ( p = 0.036, p = 0.033). There was no significant difference in the symptoms leading to EGID work‐up: incidence; morphologic features; achievement of histologic remission; medications; or family history of atopy between groups. Conclusion This retrospective biopsy‐confirmed cohort demonstrates that EGID subtype varies by transplant type, with higher rates of EoE + EoG in multivisceral recipients. Findings are exploratory and hypothesis‐generating; larger multicenter studies including more non‐liver and non‐heart transplant patients are needed.
Discordance in Total Mesorectal Excision Specimen Grading in a Prospective Phase 2 Multicenter Rectal Cancer Trial
Sylla, Patricia , Berho, Mariana, Sands, Dana R., Ricardo, Alison, Bonaccorso, Antoinette, Moshier, Erin , Letchinger, Riva , Marks, John H. , Whiteford, Mark H., McLemore, Elisabeth C. , Maykel, Justin A. , Alavi, Karim, Zaghiyan, Karen , Chadi, Sami A. , Shawki, Sherief , Pigazzi, Alessio , Albert, Matthew R. , deBeche-Adams, Teresa , Polydorides, Alexandros D. , Wexner, Steven D. , Wexner, Steven D , Hain, Élisabeth , Steele, Scott R.

Mayo Clinic

Annals of Surgery | July 14, 2023 | Volume: 278 | Issue: 3 | Pages: 452-463

10.1097/sla.0000000000005948 | PMID 37450694 Get It

Objectives: To report the results of a rigorous quality control (QC) process in the grading of total mesorectal excision (TME) specimens during a multicenter prospective phase 2 trial of transanal TME. Background: Grading of TME specimens is based on the macroscopic assessment of the mesorectum and standardized through synoptic pathology reporting. TME grade is a strong predictor of outcomes with incomplete (IC) TME associated with increased rates of local recurrence relative to complete or near complete (NC) TME. Although TME grade serves as an endpoint in most rectal cancer trials, in protocols incorporating centralized review of TME specimens for quality assurance, discordance in grading and the management thereof has not been previously described. Methods: A phase 2 prospective transanal TME trial was conducted from 2017 to 2022 across 11 North American centers with TME quality as the primary study endpoint. QC measures included (1) training of site pathologists in TME protocols, (2) blinded grading of de-identified TME specimen photographs by central pathologists, and (3) reconciliation of major discordance before trial reporting. Cohen Kappa statistic was used to assess agreement in grading. Results: Overall agreement in grading of 100 TME specimens between site and central reviewer was rated as fair, (κ = 0.35; 95% CI: 0.10–0.61; P < 0.0001). Concordance was noted in 54%, with minor and major discordance in 32% and 14% of cases, respectively. Upon reconciliation, 13/14 (93%) major discordances were resolved. Pre versus postreconciliation rates of complete or NC and IC TME are 77%/16% and 7% versus 69%/21% and 10%. Reconciliation resulted in a major upgrade (IC–NC; N = 1) or major downgrade (NC/C–IC, N = 4) in 5 cases overall (5%). Conclusions: A 14% rate of major discordance was observed in TME grading between the site and central reviewers. The resolution resulted in a major change in final TME grade in 5% of cases, which suggests that reported rates or TME completeness are likely overestimated in trials. QC through a central review of TME photographs and reconciliation of major discordances is strongly recommended.
PD-1 inhibition in advanced myeloproliferative neoplasms
Hobbs, Gabriela , Bozkus, Cansu Cimen , Moshier, Erin , Dougherty, Mikaela , Bar‐Natan, Michal , Sandy, Lonette, Johnson, Kathryn, Foster, Julia, Som, Tina T., Marble, Hetal D. , Salama, Mohamed E. , Zubizarreta, Nicole , Wadleigh, Martha , Stone, Richard M. , Iancu‐Rubin, Camelia , Cimen Bozkus, Cansu , Marble, Hetal , Salama, Mohamed , Iancu-Rubin, Camelia , Mascarenhas, John , Hobbs, Gabriela S , Macrae, Molly, Jamal, Siraj M. El , Bhardwaj, Nina , Mascarenhas, John

Mayo Clinic

Blood Advances | September 28, 2021 | Volume: 5 | Issue: 23 | Pages: 5086-5097

10.1182/bloodadvances.2021005491 | PMID 34581778 Get It

Abstract Myelofibrosis (MF) is a clonal stem cell neoplasm characterized by abnormal JAK-STAT signaling, chronic inflammation, cytopenias, and risk of transformation to acute leukemia. Despite improvements in the therapeutic options for patients with MF, allogeneic hematopoietic stem cell transplantation remains the only curative treatment. We previously demonstrated multiple immunosuppressive mechanisms in patients with MF, including increased expression of programmed cell death protein 1 (PD-1) on T cells compared with healthy controls. Therefore, we conducted a multicenter, open-label, phase 2, single-arm study of pembrolizumab in patients with Dynamic International Prognostic Scoring System category of intermediate-2 or greater primary, post-essential thrombocythemia or post-polycythemia vera myelofibrosis that were ineligible for or were previously treated with ruxolitinib. The study followed a Simon 2-stage design and enrolled a total of 10 patients, 5 of whom had JAK2V617mutation, 2 had CALR mutation, and 6 had additional mutations. Most patients were previously treated with ruxolitinib. Pembrolizumab treatment was well tolerated, but there were no objective clinical responses, so the study closed after the first stage was completed. However, immune profiling by flow cytometry, T-cell receptor sequencing, and plasma proteomics demonstrated changes in the immune milieu of patients, which suggested improved T-cell responses that can potentially favor antitumor immunity. The fact that these changes were not reflected in a clinical response strongly suggests that combination immunotherapeutic approaches rather than monotherapy may be necessary to reverse the multifactorial mechanisms of immune suppression in myeloproliferative neoplasms. This trial was registered at www.clinicaltrials.gov as #NCT03065400.
Effect of Advanced Glycation End Products on Cognition in Older Adults with Type 2 Diabetes: Results from a Pilot Clinical Trial
Lotan, Roni , Ganmore, Ithamar , Livny, Abigail , Itzhaki, Nofar, Waserman, Mark, Zacharia, Moran, Moshier, Erin , Uribarri, Jaime , Beisswenger, Paul J. , Cai, Weijing, Troen, Aron M. , Beeri, Michal Schnaider , Uribarri, Jaime , Waserman, Mark, Shelly, Shahar

Mayo Clinic

Journal of Alzheimer's Disease | July 7, 2021 | Volume: 82 | Issue: 4 | Pages: 1785-1795

10.3233/jad-210131 | PMID 34250935 Get It

Background: Dietary advanced glycation end-products (AGEs) are linked to cognitive decline. However, clinical trials have not tested the effect of AGEs on cognition in older adults. Objective: The aim of the current pilot trial was to examine the feasibility of an intervention to reduce dietary AGEs on cognition and on cerebral blood flow (CBF). Methods: The design is a pilot randomized controlled trial of dietary AGEs reduction in older adults with type 2 diabetes. Seventy-five participants were randomized to two arms. The control arm received standard of care (SOC) guidelines for good glycemic control; the intervention arm, in addition to SOC guidelines, were instructed to reduce their dietary AGEs intake. Global cognition and CBF were assessed at baseline and after 6 months of intervention. Results: At baseline, we found a reverse association between AGEs and cognitive functioning, possibly reflecting the long-term toxicity of AGEs on the brain. There was a significant improvement in global cognition at 6 months in both the intervention and SOC groups which was more prominent in participants with mild cognitive impairment. We also found that at baseline, higher AGEs were associated with increased CBF in the left inferior parietal cortex; however, 6 months of the AGEs lowering intervention did not affect CBF levels, despite lowering AGEs exposure in blood. Conclusion: The current pilot trial focused on the feasibility and methodology of intervening through diet to reduce AGEs in older adults with type 2 diabetes. Our results suggest that participants with mild cognitive impairment may benefit from an intensive dietary intervention.
Genetic effects on sleep/wake variation of seizures
Winawer, Melodie R., Shih, Jerry J. , Hunter, Jessica Ezzell , Epstein, Michael P. , Investigators, the EPGP, Sadleir, Lynette G. , Shih, Jerry, Beck, Erin S , Investigators, the EPGP

Mayo Clinic

Epilepsia | March 7, 2016 | Volume: 57 | Issue: 4 | Pages: 557-565

10.1111/epi.13330 | PMID 26948972 Get It

SummaryObjectiveThere is a complex bidirectional relationship between sleep and epilepsy. Sleep/wake timing of seizures has been investigated for several individual seizure types and syndromes, but few large‐scale studies of the timing of seizures exist in people with varied epilepsy types. In addition, the genetic contributions to seizure timing have not been well studied.MethodsSleep/wake timing of seizures was determined for 1,395 subjects in 546 families enrolled in the Epilepsy Phenome/Genome Project (EPGP). We examined seizure timing among subjects with different epilepsy types, seizure types, epilepsy syndromes, and localization. We also examined the familial aggregation of sleep/wake occurrence of seizures.ResultsSeizures in nonacquired focal epilepsy (NAFE) were more likely to occur during sleep than seizures in generalized epilepsy (GE), for both convulsive (odds ratio [OR] 5.2, 95% confidence interval [CI] 3.59–7.52) and nonconvulsive seizures (OR 4.2, 95% CI 2.48–7.21). Seizures occurring within 1 h of awakening were more likely to occur in patients with GE than with NAFE for both convulsive (OR 2.3, 95% CI 1.54–3.39) and nonconvulsive (OR 1.7, 95% CI 1.04–2.66) seizures. Frontal onset seizures were more likely than temporal onset seizures to occur during sleep. Sleep/wake timing of seizures in first‐degree relatives predicted timing of seizures in the proband.SignificanceWe found that sleep/wake timing of seizures is associated with both epilepsy syndrome and seizure type. In addition, we provide the first evidence for a genetic contribution to sleep/wake timing of seizures in a large group of individuals with common epilepsy syndromes.